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Abstract: Fungal infections in humans have historically received comparatively less attention than 
those caused by bacteria and viruses. This may, in part, stem from the relative differences in infection 
prevalence. However, the more widespread use of immunosuppressive therapy, invasive surgery and 
medical device use in modern medicine, has resulted in more frequent occurrence of human fungal 
infection. There are a number of fungi that can cause human disease. However, arguably it is species 
of the genus Candida that are most often encountered. There are over 150 Candida species that are 
widely encountered in the environment and in animal hosts, however, only a small number are 
opportunistic pathogens of humans. Candida albicans is a polymorphic yeast-like fungus and 
undoubtedly the species most often recovered from human infection. As such, the virulence of C. 
albicans and its susceptibility to antifungal agents are often investigated. More recently, the prevalence 
of infections caused by non-C. albicans Candida species have increased and amongst these, infections 
caused by Candida glabrata have received attention given the often higher tolerance to frequently used 
antifungals exhibited by this species. The papers presented in this Special Issue have focussed on 
aspects relating to host responses to Candida infection, the efficacy of novel therapeutic agents and 
also treatment regimes. The papers highlight novel findings in their respective areas, whilst also 
highlighting the need for further research in these key and largely under-researched areas of 
candidoses. 
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Several Candida species are considered to be opportunistic pathogens of humans. Generally these 
fungal microorganisms colonise mucosal surfaces of the body without causing damage. However, a 
changing environment can lead to microbial dysbiosis with an accompanying switch in the lifestyle of 
the Candida from a harmless commensal to an organism that causes disease. The manifestation of 
infection is frequently mild, and this is especially the case when topical infection occurs. However, in 
individuals who are severely immunocompromised, systemic infections can develop, and whilst these 
are relatively uncommon, they are associated with high patient mortality. The prognosis of a candidosis 
is dependent on numerous factors that relate to the virulence of the microorganism, the host’s response 
and the susceptibility of the Candida to therapeutic intervention. Compared with bacteria, the levels of 
our understanding of the virulence, host immune responses and extent of treatment options are limited. 
This Special Issue collates six papers that cover aspects relating to all of these research areas. 
Aspects of the host immune response to Candida have been considered by two articles [1, 2] in this 
Special Issue. The first of these by Braunsdorf et al., [1] is an elegant review of host immunity against 
C. albicans. The review acknowledges that whilst impaired host immunity has a significant role on the 
development of candidoses, it is also apparent that strain differences can also effect this process and 
thus influence whether commensal colonisation by C. albicans progresses to an infection state. Such 
strain-specific differences can lead to altered regulation at genomic, genetic, and epigenetic levels and 
this is made more complex by additional environmental factors.  
As previously indicated, the most prevalent forms of candidoses are topical infections, and these 
frequently arise on moist mucosal surfaces as found in the mouth and vagina. One particularly 
important form of oral candidosis is chronic hyperplastic candidosis (CHC) given its suggested link 
with malignant cellular transformation. To better understand host immune responses in this infection, 
Williams et al [2] employed immunohistochemical staining to delineate the inflammatory cell infiltrate 
mounted by the host in response to hyphal invasion of the epithelium. In CHC, the mean proportion 
of T-cells (CD3+) in tissues was 15.6%, with the majority found in the lamina propria . B-cells (CD20+) 
were comparatively in much lower proportions (1.8%). Regarding T-cells, T-helper cells (CD4+) were 
more prevalent than cytotoxic T-cells (CD8+). The study concluded that a T-helper cell dominated 
immune response occurred in CHC that was likely driven by the invading Candida and was notably 
distinct from an inflammatory cell profile encountered in control squamous cell papilloma tissue 
sections. 
One of the difficulties in the management of candidoses is the limited number of effective 
antifungal agents that do not have associated host cell toxicity or at risk of development of resistance.  
There is therefore a need for new and alternative antifungal agents that are also active against 
recalcitrant biofilms of the fungus. Increasingly, natural products such as those derived from plants, 
are being assessed for their antifungal effects. Such products frequently comprise a complex mixture of 
compounds that may each have antimicrobial effects on different microbial targets. As such, synergy 
may be evident with reduced likelihood of resistance development. In this Special Edition, two articles 
were focused on evaluation of such natural compounds. In the study by Guwca et al., [3] extracts of 
propolis (EEPs), obtained from Polish apiaries, were evaluated for their antifungal effects against C. 
albicans, with minimum fungicidal concentrations (MFC) evident between 0.08-1.25% (v/v). Synergistic 
antifungal effects against C. albicans occurred when EEPs were used in combination treatments with 
both fluconazole and voriconazole. At subinhibitory concentrations it was evident that the yeast-to-
hyphal transformation of C. albicans was inhibited. EEPs were also effective against C. albicans biofilms 
on polystyrene surfaces at concentrations between 0.04% (v/v) and >1.25% (v/v), as well as C. glabrata 
and C. krusei biofilms on polyvinyl chloride and silicone catheters.  
Similarly, in the study of Serra et al., [4], the anti-C. albicans activity of commercially available 
essential oils were compared with chlorhexidine and triclosan. Against planktonic C. albicans, all tested 
essential oils were inhibitory with minimum inhibitory concentrations (MICs) ranging between 0.06% 
(v/v) to 0.4% (v/v). Of note was that biofilms exhibited elevated resistance to these agents with 
minimum biofilm eradication concentrations reported at >1.5% (v/v). Importantly, for the essential oils 
cytotoxicity towards murine fibroblasts was at concentrations lower than the MICs which would be a 
limitation when developing these new treatments. One potential solution to reducing host cell toxicity 
from antifungal agents is to develop alternative formulations that retain desired antifungal properties 
whilst reducing damage to host cells. An excellent example of this is the use of a lipid formulation of 
amphotericin (AmB) such as AmBisome®, Abelcet® and AmB-L. The latter is a liposomal formulation 
complexed with DSPG and cholesterol which was investigated along with the deoxycholate (Deox) 
amphotericin formulation for activity against both C. albicans and C. glabrata in the study by Rodrigues 
and Henriques [5]. Experiments revealed that C. glabrata was generally more tolerant to the lipid and 
Deox formulations of AmB. When tested against biofilms the lipid formulation was deemed to have 
better therapeutic potential than AmB-Deox, as effective concentrations were at 10% of the maximum 
daily dose. 
Imbert et al [6], assessed the difficulties in preventing the development of candidemia that is 
associated with Candida biofilms on vascular catheters. One potential approach is to use very high 
concentrations of antifungal in antifungal lock therapies to sterilise catheters. This study evaluated 
existing data in the literature to determine the efficacy of a range of antifungal solutions used for lock 
therapy. It was concluded that whilst caspofungin, micafungin, anidulafungin and L-AmB were good 
candidates for lock therapy, they had to be used in combination with systemic therapy.  
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